What's next for the revitalization of downtown Ames?
AMES, Iowa — The Ames Mainstreet organization has presented a vision for downtown Ames to improve the area as one of the city's neighborhoods.
Ames Mainstreet hired the firm Bolton & Menk to conduct a study. Meetings were held along with surveys to find out more about the Ames downtown area. The survey covered the community from north of the railroad tracks to seventh street, and from Grand to Duff.
Last week the group presented their study to the Ames City Council.
'The Vision Plan for downtown Ames is really a reimagining of what this area looks like for the next 10 or 15 years,' said Travis Toliver, The Ames Main Street Director. 'We're taking a look at different ideas regarding the public space opportunities, for new development opportunities, for development with existing buildings which are already in place.'
Toliver said they hope to connect Ames with different parts of the city. Also there are some new amenities coming online soon, the Schainker Plaza, by City Hall, and the new Fitch Family Aquatic Center just west of downtown along Lincoln Way.
How to buy tickets to Indiana Fever game at Carver-Hawkeye Arena
'This is really visioning of the future of downtown, aesthetically, urban-living wise, connecting the downtown with other areas of the community, connecting with ISU more,' said Toliver. 'I'm just trying to find ways that we can better enhance the downtown area so that it's a true destination for visitors and citizens alike.'
Ames is known for its historic downtown, and unique shops. The study showed that more housing is needed, and possibly a new hotel. One hotel is on the drawing boards for just south of downtown on Lincoln Way.
'Statistically on a national average is about 5% of your full-time population should be living downtown and we certainly don't have that in Ames,' said Toliver. 'This plan represents opportunities where developers could come in and provide more housing to support all the infrastructure of the businesses that we have already existing in downtown.'
Efforts to support Main Street could include businesses which want to locate here.
Brittni Reifschneider, of Main Street Family Wellness chose to locate her business from Des Moines to downtown Ames. She and her group do mental health counseling and medication management for children.
'We wanted to come to Ames to help serve the Ames community just because they're lacking some mental health opportunities for care,' said Reifschneider. 'We just love how personable the downtown feel is. It's just like being in a small town.'
The idea of the new downtown study is to see projects being developed in and around Ames downtown.
Iowa News:
What's next for the revitalization of downtown Ames?
How to buy tickets to Indiana Fever game at Carver-Hawkeye Arena
'Picture of perseverance': Marshalltown man's legacy lives on 100+ years later in historically African-American school
Iowa bill removing gender identity from Civil Rights Act advances
WHO 13 Farm Report: Monday, February 24
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Micron to invest $200 billion in US memory facilities
Memory chip maker Micron (MU) announced on Thursday that it will invest an additional $30 billion in the US, as it looks to build out its manufacturing and research and development facilities in Idaho and New York. The move brings Micron's total US manufacturing and R&D investments up to roughly $200 billion which will create some 90,000 direct and indirect jobs, the company said. Micron is receiving about $6.5 billion in funding from the US CHIPS Act. The plans call for Micron to build a second memory manufacturing plant at its Boise, Idaho, facility and a massive chip fabrication complex in New York. The company is also updating and expanding its Virginia plant. Micron also said it expects the second Idaho plant to help it bring its advanced high-bandwidth memory (HBM) manufacturing to the US. HBM is a key component in AI data centers. 'Micron's investment in advanced memory manufacturing and HBM capabilities in the U.S., with support from the Trump Administration, is an important step forward for the AI ecosystem,' Nvidia (NVDA) CEO Jensen Huang said in a statement. 'Micron's leadership in high-performance memory is invaluable to enabling the next generation of AI breakthroughs that NVIDIA is driving. We're excited to collaborate with Micron as we push the boundaries of what's possible in AI and high-performance computing,' Huang added. All totaled, Micron says the investments will allow the company to produce 40% of its DRAM memory in the US. Its initial Idaho plant is expected to begin pumping out the hardware in 2027. Micron also says it is set to begin preparing the ground for its New York facilities later this year. 'This approximately $200 billion investment will reinforce America's technological leadership, create tens of thousands of American jobs across the semiconductor ecosystem and secure a domestic supply of semiconductors—critical to economic and national security,' Micron CEO Sanjay Mehrotra said in a statement. 'We are grateful for the support from President Trump, Secretary Lutnick and our federal, state, and local partners who have been instrumental in advancing domestic semiconductor manufacturing.' Micron isn't the only company bringing HBM production to the US, though. South Korea's SK Hynix is also building a new HBM plant in Indiana as part of a $3.8 billion construction project. The Trump administration, and the Biden administration before it, has made onshoring semiconductor manufacturing a key component of its domestic agenda, as it seeks to wean itself off of the country's dependence on foreign-made chips. Companies ranging from Intel (INTC) and TSMC (TSM) to Samsung and GlobalFounderies (GFS) and others have recently announced plans to build or upgrade their facility throughout the country, thanks in part to billions of dollars in funding through the CHIPS Act. Email Daniel Howley at dhowley@ Follow him on X/Twitter at @DanielHowley. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
15 minutes ago
- Yahoo
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Is Fidelity Select Portfolio Medical Technology and Devices (FSMEX) a Strong Mutual Fund Pick Right Now?
If you have been looking for Sector - Health funds, a place to start could be Fidelity Select Portfolio Medical Technology and Devices (FSMEX). FSMEX has a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance. Zacks categorizes FSMEX as Sector - Health, a segment packed with options. Sector - Health mutual funds offer investors a focus on the healthcare industry, one of the largest sectors in the American economy. These funds can include everything from pharmaceutical companies to medical device manufacturers and for-profit hospitals. Fidelity is responsible for FSMEX, and the company is based out of Boston, MA. Fidelity Select Portfolio Medical Technology and Devices made its debut in April of 1998, and since then, FSMEX has accumulated about $4.48 billion in assets, per the most up-to-date date available. The fund is currently managed by Edward Yoon who has been in charge of the fund since May of 2007. Investors naturally seek funds with strong performance. This fund has delivered a 5-year annualized total return of 5.12%, and it sits in the middle third among its category peers. If you're interested in shorter time frames, do not dismiss looking at the fund's 3 -year annualized total return of 3.37%, which places it in the bottom third during this time-frame. It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower. When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Over the past three years, FSMEX's standard deviation comes in at 18.22%, compared to the category average of 15.64%. Over the past 5 years, the standard deviation of the fund is 19.24% compared to the category average of 16.64%. This makes the fund more volatile than its peers over the past half-decade. Investors should note that the fund has a 5-year beta of 0.92, which means it is hypothetically less volatile than the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. With a negative alpha of -7.95, managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns. Costs are increasingly important for mutual fund investing, and particularly as competition heats up in this market. And all things being equal, a lower cost product will outperform its otherwise identical counterpart, so taking a closer look at these metrics is key for investors. In terms of fees, FSMEX is a no load fund. It has an expense ratio of 0.63% compared to the category average of 1.11%. Looking at the fund from a cost perspective, FSMEX is actually cheaper than its peers. While the minimum initial investment for the product is $0, investors should also note that there is no minimum for each subsequent investment. Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included. Overall, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively similar performance, average downside risk, and lower fees, Fidelity Select Portfolio Medical Technology and Devices ( FSMEX ) looks like a great potential choice for investors right now. Your research on the Sector - Health segment doesn't have to stop here. You can check out all the great mutual fund tools we have to offer by going to to see the additional features we offer as well for additional information. For analysis of the rest of your portfolio, make sure to visit for our full suite of tools which will help you investigate all of your stocks and funds in one place. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (FSMEX): Fund Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
